Peter G Dodd
Overview
Explore the profile of Peter G Dodd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas M, McGonagle K, Rowland P, Robinson D, Dodd P, Camino-Diaz I, et al.
J Med Chem
. 2023 Jul;
66(15):10413-10431.
PMID: 37506194
There is an urgent need for new treatments for Chagas disease, a parasitic infection which mostly impacts South and Central America. We previously reported on the discovery of GSK3494245/DDD01305143, a...
2.
McGonagle K, Tarver G, Cantizani J, Cotillo I, Dodd P, Ferguson L, et al.
Eur J Med Chem
. 2022 May;
238:114421.
PMID: 35594652
Approximately 6-7 million people around the world are estimated to be infected with Trypanosoma cruzi, the causative agent of Chagas disease. The current treatments are inadequate and therefore new medical...
3.
Thomas M, Brand S, De Rycker M, Zuccotto F, Lukac I, Dodd P, et al.
J Med Chem
. 2021 Apr;
64(9):5905-5930.
PMID: 33904304
There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported...
4.
Mudd G, Pi I, Fethers N, Dodd P, Barbeau O, Auer M
Methods Appl Fluoresc
. 2017 Nov;
3(4):045002.
PMID: 29148510
A well-documented obstacle in the synthesis of functionalized rhodamine dyes is the generation of regioisomers which are difficult to separate. These isomers occur due to the use of unsymmetrical anhydride...
5.
Kilty I, Green M, Bell A, Brown D, Dodd P, Hewson C, et al.
Chem Biol Drug Des
. 2013 Jun;
82(5):500-5.
PMID: 23745990
The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create...
6.
Millan D, Bunnage M, Burrows J, Butcher K, Dodd P, Evans T, et al.
J Med Chem
. 2011 Sep;
54(22):7797-814.
PMID: 21888439
This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease. Structure based drug...
7.
Mantell S, Gibson K, Osborne S, Maw G, Rees H, Dodd P, et al.
Bioorg Med Chem Lett
. 2009 Mar;
19(8):2190-4.
PMID: 19289283
The SAR of a series of novel pyrido[3,4-d]pyramid-4-ylamine mGluR1 antagonists is described. The multiple of the unbound K(i) in cerebrospinal fluid necessary to give morphine like analgesic effects in an...
8.
Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease
Mantell S, Stephenson P, Monaghan S, Maw G, Trevethick M, Yeadon M, et al.
Bioorg Med Chem Lett
. 2008 Feb;
18(4):1284-7.
PMID: 18243699
COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate...
9.
Owen D, Dodd P, Gayton S, Greener B, Harbottle G, Mantell S, et al.
Bioorg Med Chem Lett
. 2006 Oct;
17(2):486-90.
PMID: 17064898
A series of novel mGluR1 antagonists have been prepared. Incorporation of fragments derived from weak lead matter into a library led to enhanced potency in a new chemical series. A...